DENTSPLY SIRONA Inc (XRAY) Stock Analysis

Verdict: WATCH (do not buy)

Debt covenant amendments and GAAP losses weigh on XRAY, but restructuring savings and 5.8x forward P/E offer a turnaround entry.

Investment score: 45/100

Analysis as of

Is DENTSPLY SIRONA Inc stock worth reviewing? The TradeMates thesis

The TradeMates model rates DENTSPLY SIRONA as WATCH. Valuation appears deeply discounted at 0.5x P/S vs peer median 1.94x, but credit facility covenant amendments and structural dental market softness keep financial risk elevated.

7-factor investment score

DENTSPLY SIRONA Inc opportunities and risks

What speaks for XRAY

What speaks against XRAY

Peers and competitors

Trailing-twelve-month ratios
TickerP/EP/SEV/EBITDAGross marginNet marginFCF yield
XRAYn/a0.5x41.2x49.5%-15.0%8.1%
HAE58.9x4.1x24.8x57.4%7.1%5.3%
MMSI36.6x3.4x15.8x49.5%9.2%3.8%
MMEDn/a1.6x29.1x53.8%-10.2%-6.2%
ICUI139.4x1.9x20.8x37.6%1.4%3.7%
QDELn/a0.4xn/a44.6%-39.2%-22.1%
Peer median36.6x1.9x20.8x49.5%1.4%3.7%

Frequently asked questions about DENTSPLY SIRONA Inc (XRAY)

Is XRAY stock a good investment?

The TradeMates model rates DENTSPLY SIRONA Inc as WATCH (do not buy) with an investment score of 45/100. The TradeMates model rates DENTSPLY SIRONA as WATCH. Valuation appears deeply discounted at 0.5x P/S vs peer median 1.94x, but credit facility covenant amendments and structural dental market softness keep financial risk elevated. This is algorithmic model output, not personal investment advice.

Is XRAY stock a buy?

The TradeMates model verdict for XRAY is WATCH (do not buy) with an investment score of 45/100. Treat this as a model signal to review, not a personal buy recommendation.